

- Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer.
Katayama Y, Shimamoto T, Yamada T, Takeda T, Yamada T, Shiotsu S, Chihara Y, **Hiranuma O**, Iwasaku M, Kaneko Y, Uchino J, Takayama K.
J Clin Med. 2019 DEC 31;9(1). pii: E102. doi: 10.3390/jcm9010102.

- Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)
Hiranuma O, Uchino J, Yamada T, Chihara Y, Tamiya N, Kaneko Y, Yoshimura K, Takayama K.
Clin Lung Cancer. 2019 May;20(3):e402-e406. doi: 10.1016/j.clcc.2019.02.016. Epub 2019 Feb 27.

- Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
Yoshimura A, Yamada T, Okura N, Takeda T, Hirose K, Kubota Y, Shiotsu S, **Hiranuma O**, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K.
Cancers (Basel). 2019 Mar 15;11(3). pii: E365. doi: 10.3390/cancers11030365.

- Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Nakao A, **Hiranuma O**, Uchino J, Sakaguchi C, Kita T, Hiraoka N, Ishizuka T, Kubota Y, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Arai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K.
Oncologist. 2019 May;24(5):593-e170. doi: 10.1634/theoncologist.2019-0003. Epub 2019 Jan 16.

- The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
Yoshimura A, Yamada T, Okura N, Takeda T, Furutani W, Kubota Y, Shiotsu S, **Hiranuma O**, Nishioka N, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K.
BMC Cancer. 2018 Dec 11;18(1):1241. doi: 10.1186/s12885-018-5153-4.

- An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer.
Yoshimura A, Uchino J, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Takeda T, **Hiranuma O**, Hasegawa I, Kubota Y, Shiotsu S, Takumi C, Hiraoka N, Yamada T, Takayama K. *Medicine (Baltimore)*. 2018 Oct;97(40):e12660. doi: 10.1097/MD.00000000000012660.

- Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Nishioka N, Uchino J, **Hirai S**, Katayama Y, Yoshimura A, Okura N, Tanimura K, Harita S, Imabayashi T, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K. *J Clin Med*. 2019 Apr 3;8(4). pii: E450. doi: 10.3390/jcm8040450.

- Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
Yamada T, **Hirai S**, Katayama Y, Yoshimura A, Shiotsu S, Watanabe S, Kikuchi T, Hirose K, Kubota Y, Chihara Y, Harada T, Tanimura K, Takeda T, Tamiya N, Kaneko Y, Uchino J, Takayama K. *Cancer Med*. 2019 Apr;8(4):1521-1529. doi: 10.1002/cam4.2037. Epub 2019 Feb 21.

- Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report.
Nishioka N, Yamada T, Harita S, **Hirai S**, Katayama Y, Nakano T, Okura N, Tamiya N, Kaneko Y, Uchino J, Takayama K. *Respir Med Case Rep*. 2018 Oct 6;25:261-263. doi: 10.1016/j.rmcr.2018.10.004. eCollection 2018

- Effective combined therapy with ramucirumab for advanced pulmonary plemorphic carcinoma.
Nishioka N, Kaneko Y, Yamada T, Okura N, **Hirai S**, Takayama K. *Respirol Case Rep*. 2018 Sep 28;6(8):e00372. doi: 10.1002/rcr2.372. eCollection 2018 Nov.